Heidelberg Pharma GmbH
Schriesheimer Street 101
About Heidelberg Pharma GmbHHeidelberg Pharma offers services for the pre-clinical development of anti-cancer and anti-inflammatory drugs to the pharmaceutical and biotech industry.
CEO and CFO: Jan Schmidt-Brand
CBO: Marcel Linssen
CSO: Andreas Pahl
Please click here for Heidelberg Pharma job opportunities.
24 articles with Heidelberg Pharma GmbH
Heidelberg Pharma AG published its financial report on the first six months of 2019
Heidelberg Pharma AG announced that they will present their proprietary technology for Antibody Targeted Amanitin Conjugates as potential therapeutic modality for cancer therapy at two upcoming scientific conferences.
Heidelberg Pharma AG announced that it has received a milestone payment of 250 TUSD from its cooperation partner Telix Pharmaceuticals Limited, Melbourne, Australia,.
Heidelberg Pharma AG announced that the shareholders of the Company approved the resolutions of the administration with large majorities during the Annual General Meeting.
Heidelberg Pharma AG reported on the first three months of fiscal year 2019 (1 December 2018 - 28 February 2019) and the Group's financial figures.
Heidelberg Pharma to present its proprietary ATAC technology platform at the AACR Annual Meeting 2019
Heidelberg Pharma AG announced that it will present preclinical data on the application of its proprietary ATAC technology platform in the treatment of triple-negative breast cancer at the Annual Meeting of the American Association for Cancer Research 2019.
Heidelberg Pharma AG published its financial results and annual report for fiscal year 2018 and its outlook for 2019.
Heidelberg Pharma AG announced today that it has received a milestone payment from its cooperation partner Link Health Co., Guangzhou, China.
Heidelberg Pharma Announces Several Presentations of Research Results on ATAC Technology at the ASH Annual Meeting 2018
- Partner MD Anderson Cancer Center will present preclinical data on HDP-101 for effective 17p deletion in multiple myeloma in an oral presentation
The National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG Extend Their Collaboration to Investigate the Immuno-Competence of Urothelial Cancer Patients Receiving Immunotherapy
In recent years, checkpoint inhibitors have changed treatment paradigms in cancer.
Partner Magenta Therapeutics Exercises Option To Further Develop a Target Molecule as Antibody Targeted Amanitin Conjugate
Heidelberg Pharma AG today announced that its partner Magenta Therapeutics (NASDAQ: MGTA), Cambridge, MA, USA, exercises its option to further develop a target molecule, and will now continue the development of an Antibody Targeted Amanitin Conjugate based on the target molecule within an exclusive licensing.
Key milestones reached for GMP manufacturing of HDP-101
Heidelberg Pharma AG: Partner Telix Pharmaceuticals Files Phase III Trial for Kidney Cancer Imaging in Europe
Heidelberg Pharma AG (ISIN DE000A11QVV0 / WKN A11QVV / WL6) today announced that its partner Telix Pharmaceuticals Limited ("Telix") (ASX:TLX), has submitted a Clinical Trial Application (CTA) to initiate a Phase III trial in Europe for 89Zr-DFO-girentuximab (TLX250) for the imaging of renal (kidney) cancer with Positron Emission Tomography (PET).
Fresh off of striking a research deal with Ladenburg, Germany-based Heidelberg Pharma GmbH, Magenta Therapeutics secured $52 million.The funds will be used to advance Magenta's portfolio of bone marrow transplant medications.
Magenta Therapeutics is teaming up with Ladenburg, Germany-based Heidelberg Pharma to improve curative bone marrow transplantation.
Magenta Therapeutics and Heidelberg Pharma Sign Exclusive Multi-Target Research Agreement for the Development of Antibody Drug Conjugates
Collaboration enables and accelerates Magenta’s research and development efforts across several targeted conditioning programs for bone marrow transplant; Expands application of Heidelberg Pharma ATAC technology to new targets
The companies have agreed to test the combination of APC's proprietary site-selective protein modification technology and Heidelberg Pharma's proprietary ATAC technology in order to generate superior cancer therapeutics.
Heidelberg Pharma AG Announces Results From Research Collaboration With Heidelberg University and the DKFZ to be Presented at ASH Annual Meeting
The collaboration evaluated the efficacy of the development candidate HDP-101 on multiple myeloma cells isolated from patients. HDP-101 consists of a BCMA antibody, a specific linker and the toxin Amanitin.
The funding measure will consist of a capital increase from authorized capital and from the issue of convertible bonds.
Wilex AG: Subsidiary Heidelberg Pharma Becomes Runner Up In The Category Best New Drug Developer At World ADC Award 2017